(Q40587223)

21 September 2017

title

Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities (English)

1 reference

21 September 2017

1 reference

Expert Panel

1

1 reference

21 September 2017

publication date

1 June 2003

1 reference

Drug and Alcohol Dependence

21 September 2017

published in

1 reference

21 September 2017

volume

70

1 reference

21 September 2017

issue

3 Suppl

1 reference

21 September 2017

page(s)

S107-14

1 reference

Postmarketing surveillance for drug abuse

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900103-0

7 January 2021

Principles of drug abuse liability assessment in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900103-0

7 January 2021

Guidelines and methodological reviews concerning drug abuse liability assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900103-0

7 January 2021

Assessing abuse liability in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900103-0

7 January 2021

Principles of initial experimental drug abuse liability assessment in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900103-0

7 January 2021

Incorporating the assessment of abuse liability into the drug discovery and development process

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900103-0

7 January 2021

Conference on abuse liability assessment of CNS drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900103-0

7 January 2021

Keeping the lid on: a century of drug regulation and control

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900103-0

7 January 2021

10.1016/S0376-8716(03)00103-0

Identifiers

DOI

1 reference

21 September 2017

1 reference